907471--12/12/2008--META_FINANCIAL_GROUP_INC

related topics
{regulation, government, change}
{stock, price, share}
{loss, insurance, financial}
{loan, real, estate}
{system, service, information}
{regulation, change, law}
{customer, product, revenue}
{property, intellectual, protect}
{product, market, service}
{operation, international, foreign}
{provision, law, control}
{control, financial, internal}
{financial, litigation, operation}
{competitive, industry, competition}
{personnel, key, retain}
{condition, economic, financial}
{stock, price, operating}
Recessionary environment may adversely impact the Company s earnings and new governmental initiatives may not prove effective. Changes in interest rates could adversely affect the Company s results of operations and financial condition. The Company operates in a highly regulated environment, and changes in laws and regulations to which we are subject may adversely affect the Company s results of operations. Changes in technology could be costly. Risks Related to the Company s Business The Company operates in an extremely competitive market, and the Company s business will suffer if it is unable to compete effectively. The loss of key members of the Company s senior management team could adversely affect the Company s business. The Company s loan portfolio includes loans with a higher risk of loss. If the Company s actual loan losses exceed the Company s allowance for loan losses, the Company s net income will decrease. If the Company forecloses on and takes ownership of real estate collateral property, it may be subject to the increased costs associated with the ownership of real property, resulting in reduced revenues. Environmental liability associated with commercial lending could have a material adverse effect on the Company s business, financial condition and results of operations. If the Company fails to maintain an effective system of internal control over financial reporting, it may not be able to accurately report the Company s financial results or prevent fraud, and, as a result, investors and depositors could lose confidence in the Company s financial reporting, which could adversely affect the Company s business, the trading price of the Company s stock and the Company s ability to attract additional deposits. The Company s duties under the Sarbanes-Oxley Act of 2002 have been increasing and are anticipated to increase further in fiscal 2009. A breach of information security or compliance breach by one of the Company s agents or vendors could negatively affect the Company s reputation and business. Risks Related to the Company s Stock The price of the Company s common stock may be volatile, which may result in losses for investors. The Company s common stock is thinly traded, and thus your ability to sell shares or purchase additional shares of the Company s common stock will be limited, and the market price at any time may not reflect true value. Future sales or additional issuances of the Company s capital stock may depress prices of shares of the Company s common stock or otherwise dilute the book value of shares then outstanding. Federal regulations may inhibit a takeover, prevent a transaction you may favor or limit the Company s growth opportunities, which could cause the market price of the Company s common stock to decline. The Company may not be able to pay dividends in the future in accordance with past practice. Risks Related to Meta Payment Systems , a division of MetaBank MPS products and services are highly regulated financial products subject to extensive supervision and regulation. While some proposed legislation would benefit MPS, it is possible that new legislation could restrict MPS s current operations or change the regulatory environment in which the division s customers operate. MPS, through MetaBank, owns or is seeking a number of patents, trademarks and other forms of intellectual property with respect to the operation of its business and the protection of such intellectual property may in the future require material expenditures. Contracts with third-parties may not be renewed, may be renegotiated on terms that are not as favorable to MPS or may not be fulfilled. International expansion presents unique opportunities and challenges Existing insurance policies may not adequately protect MPS. Costs of conforming products and services to the Payment Card Industry Data Security Standards (the PCI DSS ) are costly and could continue to affect the operations of MPS. The potential for fraud in the card payment industry is significant. Part of our business depends on sales agents who do not sell our products exclusively Products and services offered by MPS involve many business parties and the possibility of collusion exists. Competition in the card industry is significant. In order to maintain an edge to its products and offerings, MPS must invest significantly in technology and research and development. Discover, MasterCard, and Visa, as well as other electronic funds networks in which MPS operates, could change their rules. Our business is heavily dependent upon the Internet and any negative disruptions to its operation could negatively impact our business.

Full 10-K form ▸

related documents
907471--1/11/2008--META_FINANCIAL_GROUP_INC
907471--12/10/2009--META_FINANCIAL_GROUP_INC
737561--2/2/2010--UCI_MEDICAL_AFFILIATES_INC
737561--4/8/2010--UCI_MEDICAL_AFFILIATES_INC
890908--11/21/2006--DYNACQ_HEALTHCARE_INC
851520--2/24/2010--EXPONENT_INC
1258602--3/1/2007--NELNET_INC
893430--12/12/2006--PEDIATRIC_SERVICES_OF_AMERICA_INC
1017813--5/9/2008--CAREGUIDE_INC
1258602--3/13/2006--NELNET_INC
1110189--3/22/2006--I_TRAX_INC
1018833--3/11/2009--QUADRAMED_CORP
1018833--3/14/2008--QUADRAMED_CORP
1101215--3/2/2009--ALLIANCE_DATA_SYSTEMS_CORP
1063561--12/28/2006--PROSPECT_MEDICAL_HOLDINGS_INC
853971--4/25/2007--STANDARD_MANAGEMENT_CORP
1139463--12/15/2008--MEDCATH_CORP
1139463--12/14/2006--MEDCATH_CORP
920148--2/26/2009--LABORATORY_CORP_OF_AMERICA_HOLDINGS
33619--12/24/2008--ESTERLINE_TECHNOLOGIES_CORP
1262279--9/12/2006--FIRST_MARBLEHEAD_CORP
26076--12/9/2009--CUBIC_CORP_/DE/
26076--12/9/2010--CUBIC_CORP_/DE/
1018833--3/16/2007--QUADRAMED_CORP
1170650--2/23/2010--MEDCO_HEALTH_SOLUTIONS_INC
1170650--2/24/2009--MEDCO_HEALTH_SOLUTIONS_INC
1047335--3/16/2007--NATIONAL_HEALTHCARE_CORP
19584--2/26/2010--CHEMED_CORP
1003472--6/1/2006--PAINCARE_HOLDINGS_INC
33619--12/22/2009--ESTERLINE_TECHNOLOGIES_CORP